Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-Arrhythmic Liability

BACKGROUND: Ibrutinib is a protein kinase inhibitor that has been widely successful in treating multiple common variations of B-cell cancers. However, an unfortunate side effect of ibrutinib is that it predisposes patients to development of atrial fibrillation. OBJECTIVES: The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Johan Z., Hansen, Finn B., Mills, Robert W., Lundby, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352262/
https://www.ncbi.nlm.nih.gov/pubmed/34396309
http://dx.doi.org/10.1016/j.jaccao.2021.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352262/
https://www.ncbi.nlm.nih.gov/pubmed/34396309
http://dx.doi.org/10.1016/j.jaccao.2021.01.009

Ejemplares similares